posttransplant cyclophosphamide

CHIME: A Novel HLA Eplet Model Predicting Non-Relapse Mortality in Haploidentical Hematopoietic Cell Transplantation

By MedXY 07/09/2026

This study introduces CHIME, a novel HLA eplet mismatch model, revealing its association with non-relapse mortality and severe aGvHD in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide, improving outcome prediction over traditional allele mismatch methods.

Hematology-Oncology news Oncology

Unified Conditioning and GVHD Prophylaxis with Fludarabine, Cyclophosphamide, and 2 Gy TBI plus Post-Transplant Cyclophosphamide in Elderly AML/MDS Patients Undergoing Haploidentical or Unrelated Donor Allo-SCT

By MedXY 06/30/2026

Fludarabine, cyclophosphamide, and low-dose TBI combined with post-transplant cyclophosphamide provide a safe and effective single platform for haploidentical and unrelated donor allo-SCT in older AML/MDS patients, showing favorable survival and GVHD outcomes.

AI Hematology-Oncology news

Choosing a Stem Cell Donor: Why Age Matters More in Some Transplants Than Others

By MedXY 05/21/2026

A major 2026 study suggests donor age affects survival differently in haploidentical and matched unrelated stem cell transplants, offering a more practical framework for choosing the best donor.

Hematology-Oncology news Pediatrics

Reduced-Intensity Thiotepa Plus Post-Transplant Cyclophosphamide Delivers Near-Universal Engraftment and Minimal GVHD in Matched Sibling Transplantation for Adolescents and Adults With Sickle Cell Disease

By MedXY 05/04/2026

A prospective multicenter study reports excellent survival, no graft failure, and very low GVHD with a thiotepa-based reduced-intensity matched sibling transplant platform for severe sickle cell disease.

Hematology-Oncology news

Post‑transplant Cyclophosphamide with Sirolimus/Cyclosporine Dramatically Lowers Chronic GVHD After Unrelated Donor PBSC Transplant Without Raising Relapse Risk

By MedXY 12/10/2025

In a randomized Phase II trial, replacing MMF with post‑transplant cyclophosphamide (PTCy) alongside sirolimus and cyclosporine in unrelated donor PBSC transplants markedly lowered chronic GVHD and improved 1‑year chronic GVHD‑free relapse‑free survival, without increasing relapse or early mortality, though severe infections rose.

Hematology-Oncology news Transplantation

Posttransplant Cyclophosphamide Appears to Neutralize the Adverse Effect of Older Unrelated Donor Age on Survival After Allogeneic HCT

By MedXY 11/12/2025

A CIBMTR registry cohort (n=10,025) found donor age predicted worse overall survival with conventional calcineurin inhibitor prophylaxis but not with posttransplant cyclophosphamide (PTCy); attenuation was driven by reduced nonrelapse mortality in PTCy recipients.